Career panelist bios:
Evelyn Nash, PhD
Evelyn Nash is a Genetic Analysis Sales Representative at Thermo Fisher Scientific, specializing in quantitative PCR (qPCR), digital PCR (dPCR), and capillary electrophoresis workflows in central Texas. After graduating from LSUHSC in 2015, she began her career as a research fellow at the Centers for Disease Control and Prevention, where she spent six years conducting clinical research, leading junior scientists, and providing guidance on CLIA-regulated testing. In 2022, Evelyn joined Thermo Fisher Scientific as a Field Application Scientist, applying her molecular biology expertise to support scientists with genetic applications. In her current role, she collaborates with researchers across academic, biotechnology, clinical, and government laboratories to identify technologies and optimize workflows that address diverse scientific challenges.
Daniel Montelongo Jauregui, PhD, D(ABMM)
Daniel Montelongo Jauregui, PhD, D(ABMM), is a Microbiology Laboratory Director at Parkland Health & Hospital Center and an Assistant Professor of Pathology at UT Southwestern Medical Center. He earned his PhD at the University of Texas at San Antonio under Dr. Lopez-Ribot, studying mixed biofilms of Candida albicans and Streptococcus gordonii. He completed a postdoctoral fellowship with Dr. Mary Ann Jabra-Rizk at the University of Maryland School of Dentistry, investigating Candida auris biofilms in murine models. He then transitioned into clinical microbiology through an ASM CPEP fellowship at the University of Utah and ARUP Laboratories. His interests span mycology, parasitology, and mycobacteriology, with a commitment to advancing diagnostics and treatments for neglected infectious diseases.
Sean Bauman, PhD
Sean Bauman, PhD is the CEO of IMMY, a biotech company that has pioneered the field of infectious disease diagnostics for more than 45 years. IMMY develops, manufactures, and distributes affordable, reliable diagnostics that save lives by connecting sick patients with proper diagnosis and early treatment. From its headquarters in Norman, OK, IMMY’s products — including its flagship CrAg LFA for cryptococcal meningitis — have reached more than 110 countries, thousands of clinics, hospitals, and laboratories, and impacted millions of patients worldwide.
Dr. Bauman’s background is broad, with over 20 years’ experience in management, infectious disease, research and development, and product design. By curating a positive culture founded on core values and innovation, Bauman has built a legacy of excellence among IMMY customers and employees. Bauman has a unique ability to inspire and empower teams to achieve a shared vision. Under his leadership, IMMY has embraced an operational excellence journey rooted in lean manufacturing and is actively advancing AI adoption across the enterprise to accelerate product development and expand global reach. This leadership has earned IMMY recognition from state, national, and global agencies for achievement in workplace culture as well as global patient impact.
In April 2026, IMMY launched IMMY Brasil in São Paulo, marking the company’s second international subsidiary and a new chapter in its global expansion. Earlier, in response to the COVID-19 pandemic, Bauman founded IMMYLabs to provide Oklahomans with efficient, accessible testing and vaccine services, standing up one of the state’s few high-complexity CLIA laboratories in record speed. Both milestones reflect the dynamic vision and transformational leadership that continue to define IMMY’s trajectory.
A native Oklahoman, Bauman graduated from the University of Oklahoma with a BS in Chemistry and went on to the University of Oklahoma Health Sciences Center to earn a PhD in Microbiology and Immunology. He has been married to his wife, Renee, for more than 30 years, and is a proud father to their three adult children, Brynn, Brooke, and Luke.